From Underperformance To Opportunity: Biotech's Case For 2025
Despite continued underperformance in 2024, the biotech sector enters 2025 with a brighter outlook driven by groundbreaking ...
Hosted on MSN1d
Vertex Pharmaceuticals (VRTX) Stock Slides as Market Rises: Facts to Know Before You Trade
Vertex Pharmaceuticals (VRTX) closed the most recent trading day at $440.68, moving -0.72% from the previous trading session. This change lagged the S&P 500's daily gain of 0.92%. Meanwhile, the Dow ...
Allogene Therapeutics Announces Benjamin M. Beneski as Senior Vice President and Chief Technical Officer
As CTO, Mr. Beneski will oversee Allogene’s technical operations, leveraging his extensive expertise in biologics manufacturing, process development, and operational leadership to carry on the work of ...